Recently, researchers investigated the microbiome of prostate fluid to know about the role of the microbiome in prostate cancer. Scientists carried out the first comprehensive and detailed comparison of the microbial ecosystems of prostatic fluid of people with and without prostate cancer. To investigate, they recruited 59 participants out of which, 32 people were prostate cancer patients and 27 people were without prostate cancer. It was found that they all had high levels of prostate-specific antigen (PSA), an enzyme secreted by the prostate. Prostate fluid samples taken from prostate cancer patients were found to be less diverse than the samples from men without cancer. Between the two groups, the researchers also measured differences in the proportions of certain species, including Enterobacter, Streptococcus and Lactococcus. However, at this stage, it is unclear that altered populations of bacteria influence the progression of prostate cancer. Measuring PSA Levels is ...
The US Food and Drug Administration has approved the
addition of overall survival (OS) data in labelling process of Gilteritinib, a
cancer drug which was indicated for adult patients who had relapsed or
refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an
FDA-approved test. FLT3 is a receptor tyrosine kinase with important roles in
cell survival and proliferation. It is mutated in one -third of AML patients. Gliteritinib
acts as an inhibitor of AXL receptor tyrosine kinase, an enzyme in humans
encoded by AXL gene . The AXL gene plays a crucial role in facilitating immune
escape and drug resistance by cancer cell, leading to metastatic cancers.
According to results, treatment with the FLT3-targeted
therapeutic Gilteritinib has shown improved survival for patients with relapsed
or refractory acute myeloid leukemia harbouring an FLT3 mutation compared with
standard chemotherapy regiments.
Get to know more such interesting news about oncology at: https://bit.ly/2KYdGMJ
Popular posts from this blog
A recent study has revealed that targeting tissues around pancreatic cancer cells may help stop their metastasis and improve chemotherapy outcomes. It was studied that how pancreatic cancer cells change their environment to enable easy metastasis, which is the main cause of pancreatic cancer-related death. The researchers discovered that some pancreatic tumours remodel the environment around them, which helps cancer cells metastasize and protects them against chemotherapy. Researchers compared tissue around tumour cells in both metastatic and non-metastatic pancreatic cancer cells. This tissue, known as matrix, acts like a glue that holds different cells or tumours together. Using mouse models, the team extracted fibroblasts-cells that produce most of the matrix from both spreading and non-spreading pancreatic tumours. It was found that cancer cells from a non-spreading tumour began to spread when mixed with fibroblasts from a spreading tumour. In this investigation, it was ...
Nano-patterned chip detects cancer in one blood drop
A research team led by researchers from the University of Kansas and KU Cancer Center has developed a device which could detect cancer in a minuscule amount of blood or blood component. The device, which is called a “3D nano-patterned chip”, identifies and diagnoses cancer by filtering for exosomes, pushing them to meet the surface of the ship for analysis. Exosomes help in sending messages to the recipient cells and communicating molecular information important in many biological functions. In the case of cancerous cells, these contain biological information that can direct tumor growth and spread in case of cancerous cells. Basically, tumors send out exosomes packaging active molecules that mirror the biological features of the parental cells. While all cells produce exosomes, tumor cells are active compared to normal cells. To test the chip’s effectiveness, the researchers used clinical samples from patients suffering from ovarian cancer, a type of cancer ...
Comments
Post a Comment